Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Integrating a Different Mechanism of Action, a different Class ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: "Integrating a Different Mechanism of Action, a different Class of ...

The abstracts are scheduled to be posted to the AACR Online Program Planner at 4:30 PM ET on Tuesday, March 25. About AACR The American Association for Cancer Research (AACR) is the first and ...

All oral presentations will be made on Wednesday, May 14, as will two of the four poster presentations ... treatments to these communities who so desperately need them.” Abstracts can be accessed ...

Title: AI-powered approaches accurately predict t(11;14) positive multiple myeloma from H&E-stained histologic sections by identifying regions demonstrating lymphoplasmacytic cytology (Abstract ...

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor ...